Scancell (LON:SCLP) Sets New 52-Week High - Should You Buy?

Key Points

• Stock jump: Scancell hit a new 52-week high (intraday GBX 14.06) and last traded at GBX 13.75, rising about 5.8% on heavy volume (~7.53 million shares).
• Mixed financials: The company reports negative EPS (GBX -0.55 last quarter) and a deeply negative net margin with analysts forecasting ~-2.54 EPS for the year, but it shows strong short-term liquidity (quick ratio 13.01) and a market cap of £142.7 million.
• Clinical progress: Scancell is a clinical-stage immunotherapy developer whose lead candidate, iSCIB1+, has shown monotherapy activity and added benefit when combined with checkpoint inhibitors in the ongoing Phase 2 SCOPE trial for advanced melanoma.

Scancell Holdings plc (LON:SCLP - Get Free Report) reached a new 52-week high on Tuesday . The stock traded as high as GBX 14.06 and last traded at GBX 13.75, with a volume of 7534431 shares changing hands. The stock had previously closed at GBX 13.

Scancell Stock Up 5.8%

The company has a quick ratio of 13.01, a current ratio of 0.56 and a debt-to-equity ratio of -193.29. The company has a fifty day moving average price of GBX 12.55 and a 200-day moving average price of GBX 11.39. The stock has a market capitalization of £142.69 million, a P/E ratio of -25.00 and a beta of 0.45.

Scancell (LON:SCLP - Get Free Report) last issued its quarterly earnings data on Thursday, January 29th. The company reported GBX (0.55) earnings per share for the quarter. Scancell had a positive return on equity of 90.29% and a negative net margin of 116.98%. As a group, research analysts forecast that Scancell Holdings plc will post -2.5361112 EPS for the current fiscal year.

About Scancell

Scancell LSE: SCLP is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.